We have an integrated discovery strategy focused on identifying synergies among neuropsychiatric, neurodegenerative, and neurological autoantibody-driven diseases to maximize the potential clinical value of our compounds in development.
Our neuroscience strategy harnesses scientific advances in four areas: human genetics, data science, biomarkers, and digital health. We leverage these advances to enable precision approaches for target and patient identification, target modulation and therapeutic focus.
Using groundbreaking science and expertise to build a promising pipeline
We’re dedicated to relentless innovation in biomarkers, data science, and clinical trials. Our goal is to identify disease subpopulations sin patients, tie targets of interest to diseases, and identify which individuals will best respond to a particular medication.
We aim to treat the right patient, with the right treatment, at the right time.
We envision a future where we go beyond formal clinical diagnosis and identify subpopulations of patients who are likely to respond to our therapies through a combination of clinical, biomarker, and digital measures. We are also prioritizing data-driven therapeutic discovery, validation, and clinical translation strategies in our disease areas of focus.
We apply learnings across disease areas leveraging insights from our work in depression to explore whether we can address other nervous system disorders.
Through scientific advancements, a broad range of expertise, and strategic partnerships, we aim to fundamentally change how these disorders are treated and make a real difference, not just for patients, but also for society.